Ence as an early stage model. Because of this, these proteins have been detected in EVs CD54/ICAM-1 Proteins Species derived from preoperative samples and recurrence samples. Summary/Conclusion: This study utilizing special recurrence samples as an early stage model shows that the identified EV-associated proteins have potential as early detection makers and warrant additional investigation. Funding: This work was supported in element by a Grantin-Aid in the Japan Science and Technology Agency (JST) through the Center of Open Innovation Network for Clever Wellness (COINS) and also a Grant-in-Aid in the Japan Agency for Health-related Investigation and Improvement (AMED) via Project for Cancer Analysis and Therapeutic BST-2/CD317 Proteins web Evolution (P-CREATE: JP18cm0106402).PF09.Exosome-encapsulated miRNA in urine as a non-invasive biomarker for prostate cancer Zhuo Li, La-Xiu Li, Yanjun Diao, Yue-yan Ma and Xiaoke Hao Department of Clinical Laboratory Medicine, Xijing Hospital, Air Force Healthcare University, Xi’an, China (People’s Republic)evaluate the diagnostic and prognostic value of urinary exosomal miRNA in PCa. Final results: 5 candidate miRNAs have been identified by NGS. Significant downregulation of urinary exosomal miR375 was observed in PCa individuals comparing with healthy controls, though miR-451a, miR-486-3p and miR-486-5p had been identified significantly upregulated. Even so, no considerable distinction was found for miR-16-2-3p. The expression degree of urinary exosomal miR-375 showed important correlation with clinical stage and bone metastasis on the patients with PCa (p 0.05). ROC evaluation demonstrated that the urinary exosomal miR-375, miR-451a, miR-486-3p and miR486-5p are able to differentiate PCa patients from healthful controls, using the AUC of 0.788, 0.757, 0.704 and 0.796, respectively. The urinary exosomal miR-375 was identified superior in discriminating localized PCa from metastatic PCa, with an AUC of 0.806. Furthermore, PCa individuals can be distinguished from BPH individuals by utilizing a panel combining urinary exosomal miR-375 and miR-451a, with an AUC of 0.726. Summary/Conclusion: These findings demonstrate that the urinary exosomal miRNA can serve as a novel and non-invasive biomarker for diagnosing and predicting the progression of PCa. Funding: Shaanxi Wellness and Household Arranging Commission Foundation Project (2016D020), Xi’an Science and Technology Bureau Foundation Project (2017121SF/YX015) and Shaanxi Organic Science Foundation Project (2018JQ8010).PF09.Unlocking the secret of salivary exosomes derived from HPV-driven oropharyngeal cancer Kai D Tanga, Yunxia Wana, Natalie Bozyka, Xi Zhanga, Liz Kennyb and Chamindie PunyadeeraaaIntroduction: Prostate cancer (PCa) is the most common malignant tumours in male urinary method. Novel and non-invasive biomarker with greater sensitivity and specificity for the diagnosis of PCa are urgently necessary. Exosomal microRNAs in circulating fluids have recently been reported to augment diagnosis and management of certain diseases, which includes cancer. The objective of this study is to explore the diagnostic worth of urinary exosomal miRNAs for PCa. Techniques: A urinary exosomal microRNA expression profiling was performed by next-generation sequencing utilizing urine samples. Then, candidate miRNAs had been selected and validated by qRT-PCR in three cohorts consisting of PCa patients, healthy controls and patients with benign prostatic hyperplasia (BPH). Receiver operator characteristic (ROC) analysis was utilised toThe College of Biomedical Sciences, Institute of Overall health and Biomedical Innovation, Queensland.